Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1379-1389

  Misra, Preeti ^a   Humblet, Valerie ^a   Pannier, Nadine ^b   Maison, Wolfgang ^b   Frangioni, John V ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

99mTc pertechnetate; Prostate specific membrane antigen; S acetylmercaptoacetyltriserine (MAS 3); Solid phase chemistry; SPECT

Indexed keywords

2 [(3 AMINO 3 CARBOXYPROPYL)(HYDROXY)(PHOSPHINYL)METHYL]PENTANE 1,5 DIOIC ACID; ADAMANTANE; MONOMER; N HYDROXYSUCCINIMIDE ESTER; ORGANIC SOLVENT; PERTECHNETIC ACID TC 99M; PROSTATE SPECIFIC MEMBRANE ANTIGEN; S ACETYLMERCAPTOACETYLTRISERINE; SERINE DERIVATIVE; SUCCINIMIDE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG PURIFICATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; ISOTOPE LABELING; MALE; SODIUM PERTECHNETATE TC 99M; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34547820232     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.040303     Document Type: Article

References (19)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Humblet V, Lapidus R, Williams LR, et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging. 2005;4:448-462.
3. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2002;1:96-101.
4. Tang H, Brown M, Ye Y, et al. Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem Biophys Res Commun. 2003;307:8-14.
5. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807-1811.
6. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227-230.
7. Humblet V, Misra P, Frangioni JV. An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging. 2006;1:196-211.
8. 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labeling. Nucl Med Biol. 1998;25:621-631.
9. Chang F, Qu T, Rusckowski M, Hnatowich DJ. NHS-MAS3: a bifunctional chelator alternative to NHS-MAG3. Appl Radial Isot. 1999;50:723-732.
10. Nakayama A, Bianco AC, Zhang CY, Lowell BB, Frangioni JV. Quantitation of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol Imaging. 2003;2:37-49.
11. De Grand AM, Frangioni JV. An operational near-infrared fluorescence imaging system prototype for large animal surgery. Technol Cancer Res Treat. 2003;2:553-562.
12. Nakayama A, del Monte F, Hajjar RJ, Frangioni JV. Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging. 2002;1:365-377.
13. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed. 1998;37:2754-2794.
14. Maison W, Frangioni JV, Pannier N. Synthesis of rigid multivalent scaffolds based on adamantane. Org Lett. 2004;6:4567-4569.
15. 99mTc labeled to a peptide by 4 methods. J Nucl Med. 2001;42:1870-1877.
16. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100.
17. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
18. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993;34:1953-1963.
19. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055-4060.